rs12251307 — IL2RA IL-2 receptor alpha chain variant

Intergenic variant 19 kb downstream of IL2RA associated with atopic dermatitis (OR 1.10), asthma, and type 1 diabetes risk — tags a regulatory locus controlling CD25 expression and T-regulatory cell homeostasis

See your personal result for IL2RA

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL2RA rs12251307 — A Shared Immune Gateway for Eczema, Asthma, and Autoimmunity

About 19 kilobases downstream of IL2RA11 IL2RA
the gene encoding CD25, the alpha chain of the high-affinity interleukin-2 receptor; CD25 is the defining surface marker of regulatory T cells (Tregs), rs12251307 sits in a region of open chromatin that functions as a long-range regulatory element for the locus. IL-2 signaling through CD25 is the central survival and activation signal for regulatory T cells22 regulatory T cells
Tregs are CD4+ immune cells that suppress excessive immune responses and maintain self-tolerance; CD25 gives Tregs preferential access to IL-2 at physiologically low concentrations. Variants across the IL2RA locus — including rs12251307 — collectively tune how much CD25 gets expressed on Treg surfaces, how sensitive those Tregs are to IL-2, and consequently how well the immune system is held in check. The T allele at this downstream position tags a configuration of the locus associated with mildly impaired immune regulation across multiple atopic and autoimmune phenotypes.

The Mechanism

rs12251307 is located on the plus strand of chromosome 10 at position 6,081,532 (GRCh38), classified as an intergenic variant with C as the GRCh38 reference allele and T as the alternate. The region around IL2RA contains multiple independent regulatory variants that together influence sIL-2RA shedding33 sIL-2RA shedding
the alpha chain of the IL-2 receptor can be cleaved and released from the cell surface as soluble IL-2RA, which competes with membrane-bound receptors for available IL-2, thereby reducing the effective IL-2 signal reaching Tregs, intron-1 enhancer activity, and promoter accessibility. The T allele at rs12251307 acts as a tag for a broader haplotype across this ~20 kb region. Because IL2RA is on the minus strand, gene regulatory elements can extend well beyond the transcribed sequence into the 3' flank, and enhancer-promoter loops at this distance are well documented in immune loci. Mechanistically, T-allele haplotypes at this locus are associated with lower Treg STAT5 phosphorylation44 Treg STAT5 phosphorylation
STAT5 is the intracellular signaling molecule activated when IL-2 binds to CD25-containing high-affinity receptor complexes; less pSTAT5 means weaker Treg activation even when IL-2 is present and reduced Treg suppressive capacity downstream of IL-2 stimulation.

The Evidence

The strongest signal comes from the 2023 Nature Communications atopic dermatitis GWAS meta-analysis. Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts55 Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts, identifying rs12251307-T as a genome-wide significant risk allele for atopic dermatitis (OR 1.10, 95% CI 1.09–1.11; p = 5×10⁻¹⁰⁷). The paper explicitly highlighted the IL2RA locus as evidence that atopic dermatitis involves systemic immune dysregulation — not just skin-barrier defects — placing it alongside classic HLA and cytokine loci. The T allele risk frequency in the atopic dermatitis cohort was ~12%.

Earlier evidence established this locus in type 1 diabetes: the Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009)66 Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009) identified the same 10p15 region at genome-wide significance (p = 1×10⁻¹³), consistent with the IL2RA locus being a shared hub for autoimmune susceptibility. A 2023 cross-trait GWAS also found rs12251307 among loci shared between rheumatoid arthritis and type 1 diabetes (Wen & Yu 2023)77 (Wen & Yu 2023). The variant also reaches genome-wide significance for asthma susceptibility (OR ~1.09, p = 2×10⁻⁹), extending the phenotypic spectrum to atopic disease more broadly. The functional biology underlying all these associations is coherent: Treg dysfunction resulting from impaired CD25 expression or IL-2 signaling permits both autoimmune attack (T1D, RA) and dysregulated type 2 immune responses (atopic dermatitis, asthma) depending on the downstream context.

Practical Actions

The T allele confers a small per-allele risk increase (OR ~1.10 per T copy). In absolute terms, the lifetime risk increase is modest but meaningful in context of a personal or family history of atopic or autoimmune conditions. Carriers cannot directly manipulate CD25 expression, but the downstream biology — Treg function and IL-2 signaling — is modulated by vitamin D status and IL-2 availability. The most clinically actionable implication for T allele carriers is awareness of early-onset warning signs across atopic and autoimmune phenotypes and timely engagement with a dermatologist or immunologist when symptoms arise.

Interactions

rs12251307 is in the same genomic locus as several other IL2RA variants already catalogued: rs210428688 rs2104286 (intron 1, soluble IL-2RA shedding), rs1272248999 rs12722489 (intron 1, estrogen-responsive enhancer), rs412950611010 rs41295061 (regulatory, T1D locus), and rs22567741111 rs2256774 (intronic). These variants are in partial linkage disequilibrium; rs12251307 represents an additional, partially independent signal at the 3' end of the locus. Compound heterozygosity across multiple IL2RA locus variants may further impair Treg function, though the specific interaction effects have not been quantified for this downstream position. The locus also interacts biologically with IL-2 pathway genes including IL2RB1212 IL2RB and IL21313 IL2; variants in these genes that reduce IL-2 production or beta-chain signaling would compound the signaling deficit created by impaired CD25 expression.

Genotype Interpretations

What each possible genotype means for this variant.

CC Low-Risk Genotype Normal

Standard CD25 expression and normal T-regulatory cell function at this locus

You carry two copies of the C reference allele at rs12251307. This configuration of the IL2RA downstream regulatory region is associated with normal CD25 expression levels on regulatory T cells and typical IL-2 signaling through the high-affinity receptor complex. About 78% of people of European descent share this genotype. Your risk for atopic dermatitis, type 1 diabetes, and asthma from this particular locus is at baseline population level.

CT One Risk Allele Intermediate

Modestly elevated risk for atopic dermatitis and related immune conditions

The IL2RA locus at 10p15.1 is a shared susceptibility hub for multiple conditions driven by dysregulated T-cell tolerance. With one T allele, your immune regulation is mildly tilted toward insufficient Treg suppression. This does not mean you will develop any of these conditions — the absolute risk increase per allele is small — but it places this locus in your broader immune risk context alongside any HLA variants, CTLA4 variants, or environmental exposures. Monitoring for early atopic symptoms is reasonable; no invasive screening is warranted.

TT Two Risk Alleles High Risk

Elevated risk for atopic dermatitis, asthma, and immune dysregulation conditions

Homozygous TT carriers sit at the high-risk end of the IL2RA locus distribution. The T allele at rs12251307 tags a broader haplotype across the IL2RA 3' regulatory region associated with lower STAT5 phosphorylation in Treg cells and reduced suppressive capacity. With two copies, the Treg signaling deficit is expected to be more pronounced. In the atopic dermatitis GWAS meta-analysis, the effect size (OR ~1.10 per allele) is additive, suggesting TT carriers have approximately 21% elevated odds for atopic dermatitis compared to CC carriers from this locus alone. This is not diagnostic — many TT carriers will never develop atopic disease — but it is clinically meaningful in context of other risk factors. The same immune dysregulation axis also underlies T1D and RA susceptibility, so this genotype is best interpreted as an overall marker of T-regulatory cell vulnerability.